多尼佩西尔改善了用多克索鲁比辛治疗的老鼠的肠道屏障破坏
Kanokphong Suparan1, Sirawit Sriwichaiin2, Chanisa Thonusin2
1Immunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand; Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, 50200, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
概括
多内西尔部分减轻了多克索鲁比辛的作用.
科学领域:
- 胃肠病学和药理学 胃肠病学和药理学
- 自主神经系统的调节规则
- 肠道微生物组研究研究
背景情况:
- 众所周知,多克索鲁比化疗会引起肠道毒性,包括屏障破坏和失生症.
- 作为一种乙胆酶抑制剂的多内佩西尔对多克索鲁比诱导的胃肠道副作用的影响仍未得到研究.
- 自主神经系统失衡与化疗引起的肠道功能障碍有关.
研究的目的:
- 在大鼠模型中研究多尼佩西尔对多克索鲁比辛诱导的肠道屏障破坏和失生症的影响.
- 评估多尼佩西尔对自主平衡,肠道微生物群和相关代谢物 (TMAO,SCFA) 在多克索鲁比治疗后的影响.
主要方法:
- 在Wistar小鼠中,给予了多克索鲁比或多克索鲁比与多尼佩西尔.
- 用心率的变化来评估自主语调.
- 分析了肠道屏障完整性,血清三甲基胺N-氧化物 (TMAO) 和短链脂肪酸 (SCFA).
主要成果:
- 德克索鲁比增加了同情度,血清内毒素和TMAO,同时破坏了肠道屏障并降低了SCFA.
- 多克索鲁比显著改变了肠道微生物群的组成.
- 多尼西尔治疗降低了交感声调,恢复了肠道屏障功能,降低了内毒素和TMAO水平,但没有改变肠道微生物群或SCFA.
结论:
- doxorubicin 诱导肠道毒性通过损害自主平衡,肠道屏障完整性,并促进失活性.
- 多尼西尔对多克索鲁比辛诱导的肠道毒性提供了部分保护,主要是通过调节自主干扰.
- 多尼的保护作用似乎独立于肠道微生物群组成或SCFA水平的直接调节.
更多相关视频
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
161
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
161
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159